Compare PYXS & AMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYXS | AMTX |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 134.2M |
| IPO Year | 2021 | 2023 |
| Metric | PYXS | AMTX |
|---|---|---|
| Price | $1.73 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $8.67 | ★ $13.38 |
| AVG Volume (30 Days) | ★ 979.2K | 743.9K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.03 | ★ 32.98 |
| EPS | N/A | ★ N/A |
| Revenue | $13,858,000.00 | ★ $77,194,000.00 |
| Revenue This Year | N/A | $24.86 |
| Revenue Next Year | $14,188.99 | $44.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 174.60 |
| 52 Week Low | $1.03 | $1.30 |
| 52 Week High | $5.55 | $3.80 |
| Indicator | PYXS | AMTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.70 | 35.46 |
| Support Level | $1.58 | $1.40 |
| Resistance Level | $2.17 | $1.87 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 2.16 | 25.53 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.